Blood test may one day personalize drug dosing after stem cell transplants
NCT ID NCT04160390
First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time
Summary
This study collects blood and stool samples from people receiving a donor stem cell transplant to understand how their bodies process the drug cyclophosphamide. By identifying biomarkers, researchers hope to develop a blood test that could predict how well a patient will respond to the drug. The study includes 72 participants with various cancers or nonmalignant diseases who are scheduled for a haploidentical transplant and will receive cyclophosphamide after transplant.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- blood and stool sample collection for biomarker analysis
- What this could lead to
- If successful, this could lead to a blood test that helps doctors personalize cyclophosphamide dosing after stem cell transplants, potentially reducing side effects and improving outcomes.
- What could go wrong
- This is an early biomarker study, not a treatment trial. It may not identify useful biomarkers, and any future blood test would require much larger studies to validate.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
72 people
The number who actually took part.
- Started
-
Nov 2018
- Expected to finish
-
Apr 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients of the City of Hope Comprehensive Cancer Center and donors.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Scheduled to undergo allogeneic hematopoietic cell transplant (HCT) with a haploidentical donor. * Allogeneic HCT scheduled to treat any underlying disease. Patients with nonmalignant diseases or cancer are eligible * Scheduled to receive post-transplant cyclophosphamide (any dose, any number of doses, any dosing frequency) as part of their post-graft immunosuppression or GVHD prophylaxis. Patients enrolled on treatment protocols that include post transplant cyclophosphamide (PTCy) but do not include mycophenolate mofetil (MMF) or tacrolimus can participate * Willingness to: * Provide blood * Permit medical record review
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Allogeneic hematopoietic stem cell transplant recipient are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Pronged attack shrink advanced solid tumors?
- Can tumor avatars reveal why cancer hits minorities harder?
- New imaging agent aims to sharpen cancer detection
- Could a daily pill tame rare cancers in teens? new trial investigates
- Could your genes hold the key to cancer risk? scientists investigate families
- Could cousins be as good as siblings for stem cell donation?